Title |
EBV-gp350 Confers B-Cell Tropism to Tailored Exosomes and Is a Neo-Antigen in Normal and Malignant B Cells—A New Option for the Treatment of B-CLL
|
---|---|
Published in |
PLOS ONE, October 2011
|
DOI | 10.1371/journal.pone.0025294 |
Pubmed ID | |
Authors |
Romana Ruiss, Simon Jochum, Ralph Mocikat, Wolfgang Hammerschmidt, Reinhard Zeidler |
Abstract |
gp350, the major envelope protein of Epstein-Barr-Virus, confers B-cell tropism to the virus by interacting with the B lineage marker CD21. Here we utilize gp350 to generate tailored exosomes with an identical tropism. These exosomes can be used for the targeted co-transfer of functional proteins to normal and malignant human B cells. We demonstrate here the co-transfer of functional CD154 protein on tailored gp350+ exosomes to malignant B blasts from patients with B chronic lymphocytic leukemia (B-CLL), rendering B blasts immunogenic to tumor-reactive autologous T cells. Intriguingly, engulfment of gp350+ exosomes by B-CLL cells and presentation of gp350-derived peptides also re-stimulated EBV-specific T cells and redirected the strong antiviral cellular immune response in patients to leukemic B cells. In essence, we show that gp350 alone confers B-cell tropism to exosomes and that these exosomes can be further engineered to simultaneously trigger virus- and tumor-specific immune responses. The simultaneous exploitation of gp350 as a tropism molecule for tailored exosomes and as a neo-antigen in malignant B cells provides a novel attractive strategy for immunotherapy of B-CLL and other B-cell malignancies. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Netherlands | 3 | 4% |
Germany | 1 | 1% |
United Kingdom | 1 | 1% |
Argentina | 1 | 1% |
United States | 1 | 1% |
Unknown | 72 | 91% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 17 | 22% |
Researcher | 17 | 22% |
Student > Bachelor | 7 | 9% |
Student > Doctoral Student | 5 | 6% |
Professor > Associate Professor | 5 | 6% |
Other | 10 | 13% |
Unknown | 18 | 23% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 28 | 35% |
Biochemistry, Genetics and Molecular Biology | 12 | 15% |
Medicine and Dentistry | 9 | 11% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
Immunology and Microbiology | 3 | 4% |
Other | 3 | 4% |
Unknown | 21 | 27% |